Vickers A J, Smith C
Integrative Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021, USA.
Cochrane Database Syst Rev. 2004(1):CD001957. doi: 10.1002/14651858.CD001957.pub2.
Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum is a patented, commercially available homoeopathic medicine. The rationale for its use in influenza comes from the homoeopathic principle of 'let like be cured by like'. The medicine is manufactured from wild duck heart and liver, which are said to be reservoirs for influenza viruses.
To determine whether homoeopathic Oscillococcinum or similar medicines are more effective than placebo in the prevention and treatment of influenza and influenza-like syndromes.
The Cochrane Central Register of Controlled Trials (CENTRAL) issue 2, 2003; MEDLINE (January 1966 to June 2003) and EMBASE (1980 to June 2003) were searched, using the term "homeopathy" with "influenza", "respiratory tract", "infection", "cough", "virus" and "fever". The manufacturers of Oscillococcinum were contacted for information.
Placebo-controlled trials of Oscillococcinum or homeopathically-prepared influenza virus, influenza vaccine or avian liver in the prevention and treatment of influenza and influenza-like syndromes.
Two reviewers extracted data and assessed methodological quality independently.
Seven studies were included in the review, three prevention trials (n = 2265) and four treatment trials (n = 1194). Only for two studies was there sufficient information to complete data extraction fully. There was no evidence that homoeopathic treatment can prevent influenza-like syndrome (relative risk 0.64, 95% confidence interval 0.28 to 1.43). Oscillococcinum treatment reduced length of influenza illness by 0.28 days (95% confidence interval 0.50 to 0.06). Oscillococcinum also increased the chance of a patient considering treatment effective (relative risk 1.08; 95% CI 1.17, 1).
REVIEWER'S CONCLUSIONS: Though promising, the data are not strong enough to make a general recommendation to use Oscillococcinum for first-line treatment of influenza and influenza-like syndrome. Further research is warranted but required sample sizes are large. Current evidence does not support a preventative effect of Oscillococcinum-like homeopathic medicines in influenza and influenza-like syndromes.
流感是一种极具传染性的病毒性疾病,在冬季尤为常见。奥司他韦是一种获得专利的、可在市场上买到的顺势疗法药物。其用于治疗流感的理论依据源自顺势疗法的“以类治类”原则。该药物由野鸭的心脏和肝脏制成,据说这些部位是流感病毒的储存库。
确定顺势疗法的奥司他韦或类似药物在预防和治疗流感及流感样综合征方面是否比安慰剂更有效。
检索了Cochrane对照试验中心注册库(CENTRAL,2003年第2期)、MEDLINE(1966年1月至2003年6月)和EMBASE(1980年至2003年6月),使用了“顺势疗法”与“流感”、“呼吸道”、“感染”、“咳嗽”、“病毒”和“发热”等相关术语。还联系了奥司他韦的制造商以获取信息。
关于奥司他韦或顺势疗法制备的流感病毒、流感疫苗或禽类肝脏在预防和治疗流感及流感样综合征方面的安慰剂对照试验。
两名综述作者独立提取数据并评估方法学质量。
该综述纳入了7项研究,3项预防试验(n = 2265)和4项治疗试验(n = 1194)。只有两项研究有足够信息来完全完成数据提取。没有证据表明顺势疗法治疗可预防流感样综合征(相对危险度0.64,95%置信区间0.28至1.43)。奥司他韦治疗使流感病程缩短了0.28天(95%置信区间0.50至0.06)。奥司他韦还增加了患者认为治疗有效的可能性(相对危险度1.08;95%置信区间1.17,1)。
尽管有前景,但数据力度不足以普遍推荐使用奥司他韦进行流感及流感样综合征的一线治疗。有必要进行进一步研究,但所需样本量很大。目前的证据不支持类似奥司他韦的顺势疗法药物对流感及流感样综合征有预防作用。